Limits...
Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy.

Wang XB, Jiang XR, Yu XY, Wang L, He S, Feng FY, Guo LP, Jiang W, Lu SH - Cancer Sci. (2014)

Bottom Line: The results showed that the serum MIC1 of ESCC was significantly higher than normal groups (P < 0.001), and was positively associated with tumor invasion (P = 0.030) as well as lymph node metastasis (P = 0.007).The antibody of MIC1 inhibited the tumor growth (P < 0.001), and showing preference for tumor tissues in xenograft model.The decreased formation of neovascularization lumen may be involved in the mechanism.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Show MeSH

Related in: MedlinePlus

Level of macrophage inhibitory factor 1 (MIC1) in serum samples. The number of cases for each group is indicated below the x-axis. In the box plots, the lines denote the 2.5th, 25th, median, 75th and 97.5th percentiles for each. (a) Serum MIC1 in healthy subjects and esophageal squamous cell carcinoma (ESCC) patients. (b) Serum MIC1 in ESCC patients grouped by tumor node metastasis (TNM) stage. (c) Serum MIC1 classified according to T stage. (d) Serum MIC1 classified according to lymph node metastasis. (e) Serum MIC1 of ESCC patients before (pre-op) and 1 month after (1 month post-op) surgical resection. (f) Serum MIC1 of relapsed ESCC patients and corresponding pre-op and post-op MIC1 level.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317821&req=5

fig01: Level of macrophage inhibitory factor 1 (MIC1) in serum samples. The number of cases for each group is indicated below the x-axis. In the box plots, the lines denote the 2.5th, 25th, median, 75th and 97.5th percentiles for each. (a) Serum MIC1 in healthy subjects and esophageal squamous cell carcinoma (ESCC) patients. (b) Serum MIC1 in ESCC patients grouped by tumor node metastasis (TNM) stage. (c) Serum MIC1 classified according to T stage. (d) Serum MIC1 classified according to lymph node metastasis. (e) Serum MIC1 of ESCC patients before (pre-op) and 1 month after (1 month post-op) surgical resection. (f) Serum MIC1 of relapsed ESCC patients and corresponding pre-op and post-op MIC1 level.

Mentions: We detected increased levels of MIC1 in the serum of ESCC patients compared with healthy controls (P < 0.001; Fig. 1a). The serum MIC1 levels varied by Tumor Node Metastasis (TNM) staging (Fig. 1b) and were positively correlated with TNM staging as revealed by Spearman bivariate correlation analysis (P = 0.009, r = 0.154). Data on the depth of tumor invasion and lymph node metastasis were available in 249 cases (who had surgery) out of the 286 ESCC patients, among which the level of MIC1 in the T3–4 stage group was significantly higher than that in T1–2 group (P = 0.030; Fig. 1c) and that of N1–3 was significantly higher than that in N0 group (P = 0.007; Fig. 1d). The results also showed that increased levels of MIC1 were not significantly correlated with age, gender, or remote metastasis.


Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy.

Wang XB, Jiang XR, Yu XY, Wang L, He S, Feng FY, Guo LP, Jiang W, Lu SH - Cancer Sci. (2014)

Level of macrophage inhibitory factor 1 (MIC1) in serum samples. The number of cases for each group is indicated below the x-axis. In the box plots, the lines denote the 2.5th, 25th, median, 75th and 97.5th percentiles for each. (a) Serum MIC1 in healthy subjects and esophageal squamous cell carcinoma (ESCC) patients. (b) Serum MIC1 in ESCC patients grouped by tumor node metastasis (TNM) stage. (c) Serum MIC1 classified according to T stage. (d) Serum MIC1 classified according to lymph node metastasis. (e) Serum MIC1 of ESCC patients before (pre-op) and 1 month after (1 month post-op) surgical resection. (f) Serum MIC1 of relapsed ESCC patients and corresponding pre-op and post-op MIC1 level.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317821&req=5

fig01: Level of macrophage inhibitory factor 1 (MIC1) in serum samples. The number of cases for each group is indicated below the x-axis. In the box plots, the lines denote the 2.5th, 25th, median, 75th and 97.5th percentiles for each. (a) Serum MIC1 in healthy subjects and esophageal squamous cell carcinoma (ESCC) patients. (b) Serum MIC1 in ESCC patients grouped by tumor node metastasis (TNM) stage. (c) Serum MIC1 classified according to T stage. (d) Serum MIC1 classified according to lymph node metastasis. (e) Serum MIC1 of ESCC patients before (pre-op) and 1 month after (1 month post-op) surgical resection. (f) Serum MIC1 of relapsed ESCC patients and corresponding pre-op and post-op MIC1 level.
Mentions: We detected increased levels of MIC1 in the serum of ESCC patients compared with healthy controls (P < 0.001; Fig. 1a). The serum MIC1 levels varied by Tumor Node Metastasis (TNM) staging (Fig. 1b) and were positively correlated with TNM staging as revealed by Spearman bivariate correlation analysis (P = 0.009, r = 0.154). Data on the depth of tumor invasion and lymph node metastasis were available in 249 cases (who had surgery) out of the 286 ESCC patients, among which the level of MIC1 in the T3–4 stage group was significantly higher than that in T1–2 group (P = 0.030; Fig. 1c) and that of N1–3 was significantly higher than that in N0 group (P = 0.007; Fig. 1d). The results also showed that increased levels of MIC1 were not significantly correlated with age, gender, or remote metastasis.

Bottom Line: The results showed that the serum MIC1 of ESCC was significantly higher than normal groups (P < 0.001), and was positively associated with tumor invasion (P = 0.030) as well as lymph node metastasis (P = 0.007).The antibody of MIC1 inhibited the tumor growth (P < 0.001), and showing preference for tumor tissues in xenograft model.The decreased formation of neovascularization lumen may be involved in the mechanism.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Show MeSH
Related in: MedlinePlus